Cargando…
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
Proteasomal inhibition revolutionized myeloma therapies in this decade of novel agents. The only US Food and Drug Administration approved proteasome inhibitor so far, bortezomib effectively targets the constitutive proteasome subunit β5 of the 26S proteasome. Bortezomib induces high and quality resp...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563316/ https://www.ncbi.nlm.nih.gov/pubmed/23386784 http://dx.doi.org/10.2147/BTT.S24580 |